Introduction {#sec1}
============

Human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) offer a potentially limitless source of cells for industrial and clinical translation, and the ever-advancing field of cellular reprogramming has redefined the limits of cell plasticity ([@bib46]). Meanwhile, cell culture and production technologies are rapidly improving, and the first instances of pluripotent-cell-derived therapies have entered clinical trials ([@bib33]).

Amidst this broadening field, hepatocyte generation is gathering interest with industrial and clinical parties due to its relevance in the areas of drug development, cell therapy, and disease modeling. While the scope of what could be achieved is wide, a number of obstacles remain before human pluripotent stem cell (hPSC) technologies can be adopted for widespread use. On the one hand are the technical challenges relating to scalability, definition, and reproducibility, while from a basic research perspective, many unanswered questions remain regarding the development of an adult phenotype, the mechanisms of cell reprogramming, and the role of the tissue culture microenvironment.

Early protocols for the generation of hepatocytes from pluripotent cells relied on the use of embryoid body formation ([@bib4; @bib5; @bib18]). This method involves the creation of cell aggregates and the spontaneous differentiation of the pluripotent population to a mixed population of cells representing the three germ layers ([@bib19]). Notable improvements in efficiency and functionality have since been achieved by various groups, which based their protocols on developmental signaling and utilized adherent culture conditions. However, all directed differentiation protocols for hepatocyte-like cells (HLCs) published to date have relied on the use of recombinant growth factors such as activin A, Wnt3a, hepatocyte growth factor (HGF), oncostatin M (OSM), fibroblast growth factor 4 (FGF4), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and bone morphogenetic protein 4 (BMP4) ([@bib1; @bib8; @bib9; @bib11; @bib17; @bib24; @bib35; @bib37; @bib42; @bib47]).

Some recent progress has been made in replacing growth factors for the differentiation of mesoderm and ectoderm ([@bib10; @bib23]), and efforts have been undertaken to find suitable candidates for the production of definitive endoderm (DE), exemplified by the Melton group, who identified IDE1 and 2 ([@bib7]). Recent studies have also demonstrated the utility of other small molecules in priming pluripotent cells for differentiation toward endoderm ([@bib44]) and mesoderm ([@bib45]). To date, however, further endodermal differentiation has only been performed in combination with other recombinant growth factors (for a review, see [@bib15]).

A number of publications have demonstrated that Wnt signaling is required to specify DE ([@bib13; @bib29]), and we have found that a pulse of GSK-3 inhibition is sufficient to produce populations of DE at a high efficiency. We are then able to direct the small-molecule-generated population of DE to functional HLCs with a combination of small molecules, namely DMSO, dexamethasone (DEX), and an HGF receptor agonist N-hexanoic-Tyr, Ile-(6) aminohexanoic amide (dihexa) ([@bib27]). This stepwise approach is able to generate HLCs at high efficiency, without the inclusion of growth factors ([Figure 1](#fig1){ref-type="fig"}). The differentiated cells demonstrate similar levels of function to those derived via published growth-factor-based approaches.

Results {#sec2}
=======

Production of DE Using GSK-3 Inhibition: Phase I {#sec2.1}
------------------------------------------------

The ability to produce hepatocytes from hPSCs that have utility in both clinical and research arenas will require methodologies that are robust in terms of efficiency and reproducibility. The majority of methodologies to date are far from this and also reliant on recombinant growth factors to direct cellular fate. This will prove a major hurdle if these cells are to be utilized in a therapeutic environment. We have therefore developed a differentiation procedure that is devoid of growth factors and driven by small molecules. The procedure is notionally trisected into three phases inducing DE differentiation (phase I), hepatic specification (phase II), and hepatocyte maturation (phase III).

Following studies of the utility of GSK-3 inhibition in priming pluripotent cells for endodermal differentiation ([@bib44]) and reports that Wnt/β-catenin signaling regulates *SOX17* expression and is essential for endoderm formation ([@bib13]), we set out to establish whether we could use this approach as a starting point for the generation of functional hepatocytes. We initially established the conditions for DE differentiation in the hESC line H1. Through a 24-hr treatment with 3 μM CHIR99021, followed by 24 hr of non-directed differentiation in RPMI-B27, we were able to guide hPSCs through developmentally relevant stages to produce a population of DE ([Figure 2](#fig2){ref-type="fig"}A). Over a 48-hr period, we observed dynamic changes in the gene expression pattern ([Figure 3](#fig3){ref-type="fig"}). By 48 hr, we observed elevated expression of DE markers such as *FOXA2*, *GSC*, *SOX17*, *HHEX*, and *CER1* ([@bib2; @bib6; @bib21; @bib28; @bib31]). In addition, early events of the differentiation indicated transition through a primitive streak (PS) intermediate. We observed a rapid upregulation of *NODAL* within 4 hr of exposure to CHIR99021, which is indicative of a transition toward a PS population ([Figure 3](#fig3){ref-type="fig"}) ([@bib25]). This was followed by induction of the PS markers *T* and *GSC* ([Figure 3](#fig3){ref-type="fig"}). The markers *SOX17*, *GSC*, *FOXA*2, and *MIXL1* are expressed in extra-embryonic endodermal lineages as well as DE. In order to demonstrate that our differentiation procedure was not producing primitive endoderm, we examined the levels of *SOX7* and observed no upregulation during our procedure ([Figure 2](#fig2){ref-type="fig"}A). The observed patterns of expression are similar to those seen with a 3-day treatment of activin A and Wnt3a or a 5-day treatment of activin A ([@bib12; @bib17]). These changes in gene expression were accompanied by morphological changes; the cells shifted from a pluripotent morphology to dense, bright clusters at 24 hr, followed by a petal-like morphology at 48 hr ([Figure 2](#fig2){ref-type="fig"}B). At the 48-hr time point (phase I endpoint), we observed co-expression of FOXA2 and SOX17 at the protein level using immunofluorescence ([Figure 2](#fig2){ref-type="fig"}C). We then compared treatments with activin A/Wnt3a, CHIR99021, and vehicle control and found equivalent co-expression of the DE proteins FOXA2 and SOX17 by immunofluorescence in the growth-factor- and small-molecule-treated cells ([Figure 2](#fig2){ref-type="fig"}C) and no co-expression in the control (data not shown). Next, we assessed whether GSK-3 inhibition was a generic mechanism to drive hPSCs to DE. [Figure 2](#fig2){ref-type="fig"}C demonstrates the utility of an alternative GSK-3 inhibitor (BIO, 1 μM) to produce FOXA2/SOX17-positive cells under the same conditions, suggesting that GSK-3 inhibition followed by its removal is responsible for commitment to DE. It is well documented that BIO and CHIR99021 are potent pharmacological GSK-3-specific inhibitors that result in activation of the Wnt signaling pathway ([@bib32; @bib36]), so we next assessed the ability of the protein Wnt3a alone to drive differentiation toward DE. [Figure 2](#fig2){ref-type="fig"}C demonstrates that treatment with Wnt3a was sufficient to produce populations of cells that expressed the DE markers FOXA2 and SOX17. This observation indicates that Wnt3a treatment alone can facilitate the production of DE and that the inclusion of activin A is not necessary for DE production in vitro. All treatments described gave similar efficiencies with respect to FOXA2- and SOX17-positive cells: 78%--85% for FOXA2 and 79%--87% for SOX17 ([Figure 2](#fig2){ref-type="fig"}D).

Hepatic Specification through DMSO Treatment of Definitive Endoderm: Phase II {#sec2.2}
-----------------------------------------------------------------------------

Following the production of DE through small-molecule stimulation, the next step was to specify a hepatic fate. We explored potential routes to efficiently produce an AFP/HNF4A-positive hepatic progenitor population. There are numerous reports of the utility of the small molecule DMSO in stem cell differentiation and specifically in the generation of hepatic progenitors ([@bib17; @bib30; @bib39; @bib42]). Therefore, we used a well-established method consisting of a 5-day treatment with 1% DMSO. On subjecting DE to phase II conditions (DMSO), we observed a rapid change in morphology and a spurt of proliferation. After the 5 days of treatment, we observed 87% co-expression of AFP and HNF4A, as assessed by immunofluorescence ([Figures 4](#fig4){ref-type="fig"}A and 4B). This was comparable to activin A/Wnt3a followed by DMSO treatment, in line with previous reports ([Figures 4](#fig4){ref-type="fig"}A and 4B). In addition, the cells exhibited typical hepatocyte progenitor morphology as assessed by phase contrast microscopy ([Figure 4](#fig4){ref-type="fig"}C). The levels of AFP/HNF4A co-expression observed are indicative that this phase of the differentiation is extremely efficient ([Figure 4](#fig4){ref-type="fig"}B). Gene expression was analyzed after the end of hepatic specification by qRT-PCR ([Figure 4](#fig4){ref-type="fig"}D), and the panel shows a repertoire of hepatic progenitor markers that were expressed including *AFP*, *CEBPA*, *FOXA2*, *GATA4*, *HNF4A*, *PROX1*, *TBX3*, and *TTR.* To assess the differentiation of DE to hepatic progenitors (hepatoblasts), we monitored the gene expression levels of several key developmental markers, which are known to regulate hepatoblast formation in vivo, during the 5-day phase II protocol ([@bib34]). We observed that both small-molecule- and growth-factor-derived DE (hESC line H1) followed a similar trajectory toward hepatic progenitors ([Figure 5](#fig5){ref-type="fig"}). During differentiation to hepatic progenitors, we observed maintenance of *FOXA2* levels and an induction of *GATA4*, both of which are known to be pioneer factors critical to promote the hepatic gene expression program ([@bib20]). Over the 5 days, there was an increase in expression of *PROX1* and *TBX3*, which are believed to interact in vivo to promote the migration and proliferation of hepatoblasts from the primary liver bud ([@bib38; @bib26]). Furthermore, we analyzed several key regulators and markers of hepatocyte differentiation and observed strong induction of *CEBPA*, *HNF4A*, *TTR*, and *AFP*.

Production of HLCs via Dexamethasone and the HGF Receptor Agonist Dihexa: Phase III {#sec2.3}
-----------------------------------------------------------------------------------

The final stage of HLC differentiation (hepatic maturation) has been performed by many groups using a wide range of growth factors such as HGF, OSM, FGF4, VEGF, and EGF ([@bib15]). We assessed the literature landscape to find potential small-molecule mimetics of growth factors involved in hepatocyte maturation and identified a potent, stable HGF receptor agonist, N-hexanoic-Tyr, Ile-(6) aminohexanoic amide (dihexa). This molecule was originally developed as a potential therapeutic intervention for neurodegenerative disorders such as Alzheimer's disease ([@bib27]). In addition, we utilized the small-molecule glucocorticoid mimetic dexamethasone (DEX), which is well established in hepatocyte maturation procedures.

We tested a number of base media to establish the optimal concentrations of DEX and dihexa. We initially used the proprietary media HepatoZYME (Life Technologies) and established the optimal concentrations of DEX and dihexa as being 100 nM for each (data not shown). However, HepatoZYME is a proprietary reagent and contains the growth factor EGF and thus was unsuitable for this application ([@bib14]). We next assessed William's base medium, as this is used in a number of protocols for hepatocyte differentiation. Both DEX and dihexa were required, and the above concentrations gave the best results in terms of morphology and function, but this media was not optimal in our hands (data not shown). We finally settled on a modified formulation of Leibovitz L-15 medium (L-15), which has been described in the literature as a standard method to generate mature hepatocytes ([@bib17; @bib42]). L-15 medium was supplemented with DEX and dihexa (both at 100 nM), which led to the production of cells displaying typical hepatocyte morphology at the endpoint of the small-molecule-driven differentiation protocol ([Figure 6](#fig6){ref-type="fig"}A). The cells were large and angular with bright junctions and in some instances contained multiple nuclei. The resulting HLCs demonstrated expression of the hepatocyte markers albumin (ALB), HNF4A, alpha-1-antitrypsin (A1AT), and AFP by immunofluorescence ([Figures 6](#fig6){ref-type="fig"}B--6D). Comparable data can be seen for growth-factor-based differentiation in [Figures 6](#fig6){ref-type="fig"}B--6D. We observed comparable efficiencies of differentiation between the growth-factor and small-molecule approaches by assessing ALB/HNF4A, A1AT, and AFP ([Figure 6](#fig6){ref-type="fig"}E). To corroborate that the source of the HLCs is from DE rather than from yolk sac, we demonstrated that the DE origin marker *CYP7A1* was expressed ([@bib3]) ([Figure 6](#fig6){ref-type="fig"}F). To ensure that the protocol was equivalent to previously described growth-factor-based methods, we produced functional hepatocytes as described by Hay and colleagues ([@bib17]) (see [Figures 6](#fig6){ref-type="fig"}B--6D) for validation. Gene expression was analyzed by qRT-PCR ([Figure 7](#fig7){ref-type="fig"}A), and the panel shows a repertoire of hepatic markers that were expressed: *A1AT (SERPINA1)*, *AFP*, *ALB*, *APOA2*, *ASGR1*, *CYP3A4*, *HNF4A*, *TDO2*, and *TTR*. The observed relative levels of expression were very similar irrespective of being derived via the growth-factor- or small-molecule-based protocol ([Figure 7](#fig7){ref-type="fig"}A). We observed similar level of expression with respect to fetal hepatocytes for *A1AT (SERPINA1)*, *APOA2*, *ASGR1*, *HNF4A*, and *TTR.* However, we observed higher levels of expression of *AFP* for both small-molecule- and growth-factor-derived HLCs compared to adult and fetal hepatocytes. In all cases, except for *AFP*, we observed higher levels of expression of all hepatic markers in primary adult hepatocytes.

Small-Molecule-Derived HLCs Demonstrate Hepatic Function {#sec2.4}
--------------------------------------------------------

Above, we have shown that small-molecule-derived HLCs (smHLCs) exhibit hepatic morphology and expression of hepatocyte-specific markers at the transcriptional and protein levels. We next assessed whether smHLCs displayed functional hepatic characteristics. An important function of hepatocytes is the ability to clear xenobiotics via metabolism through the cytochrome P450 isoenzymes. We assessed smHLCs for their metabolic potential, as compared to growth-factor-derived HLCs. The cytochrome P450 enzymes (CYP) are critical in drug metabolism, in particular CYP1A2 and CYP3A4. We assessed the function of these CYPs in terms of their basal activity and their ability to be induced by rifampicin (CYP3A4) and omeprazole (CYP1A2). We observed higher basal CYP activity in the smHLCs as compared to hESC H1 controls for both CYP1A2 and 3A4 ([Figure 7](#fig7){ref-type="fig"}B). On challenge with known inducers of these enzymes, we observed significant induction of both CYPs, to a similar degree as in growth-factor-derived HLCs ([Figure 7](#fig7){ref-type="fig"}B). Another key function of hepatocytes is the production of serum proteins, so we examined the ability of the smHLCs to secrete albumin, alpha-1-antitrypsin, and fibronectin by ELISA. All three proteins were detected in the medium at levels similar to those seen from growth-factor-derived cells ([Figure 7](#fig7){ref-type="fig"}C). Another function tested was the ability to store glycogen. smHLCs were stained with periodic acid Schiff (PAS) and counterstained with H&E. We observed extensive cytoplasmic staining (pink to purple), indicative of glycogen storage, at levels similar to those observed in growth-factor-derived hepatocytes ([Figure 7](#fig7){ref-type="fig"}D). We also examined the uptake of indocyanine green (ICG) in smHLCs; after a brief treatment, ICG-positive cells were clearly visible ([Figure 7](#fig7){ref-type="fig"}E).

smHLCs Can Be Derived from Multiple Human Pluripotent Stem Cell Lines {#sec2.5}
---------------------------------------------------------------------

An important attribute of any differentiation methodology is the ability to translate it to other cell lines. This is especially important in the case of hiPSCs, as these will provide a basis to model hepatic disease and potentially lead to the development of personalized medicine. In addition, the ability to derive hepatocytes of a defined genotype will be of utility in the areas of toxicology and drug development. To test this, we assessed the potential of a number of hPSC lines. We tested one additional hESC line (207) and three different hiPSC clones derived from the fibroblast line Detroit 551 (RA, RB, and RC), using the conditions applied to the hESC line H1.

Through an initial 24-hr treatment with 3 μM CHIR99021, followed by 24 hr of non-directed differentiation in RPMI-B27, we observed that the differentiation was very inefficient and did not produce the predicted morphology (data not shown) as previously observed for the hESC line H1 ([Figure 2](#fig2){ref-type="fig"}B). We next performed a titration of the small molecule CHIR99021 (1--10 μM) in RPMI-B27 ± insulin ([Figure S1](#app2){ref-type="sec"}C). The optimal concentration for CHIR99021 was 4 μM in RPMI-B27 minus insulin in all cases. Over a 48-hr period, we observed dynamic changes in the gene expression pattern ([Figure S2](#app2){ref-type="sec"}A) similar to those previously observed for the hESC line H1. On completion of phase I (48 hr), we observed elevated expression of DE markers such as *FOXA2*, *GSC*, *SOX17*, *HHEX*, and *CER1*. These changes in gene expression were accompanied by morphological changes consistent with the hESC line H1 differentiation above ([Figure S2](#app2){ref-type="sec"}B). At the 48-hr time point (phase I endpoint), we observed co-expression of FOXA2 and SOX17 at the protein level using immunofluorescence ([Figure S2](#app2){ref-type="sec"}C). All lines gave similar efficiencies with respect to FOXA2- and SOX17-positive cells: 81%--84% for FOXA2 and 79%--82% for SOX17 ([Figure S2](#app2){ref-type="sec"}D). To ensure that hiPSCs were following a developmentally relevant route, we assessed the timing of key events in DE specification. [Figure S3](#app2){ref-type="sec"} shows induction of the PS markers *T*, *GSC*, and *NODAL* in the first 24 hr. This is followed by specification to definitive endoderm indicated by robust induction of *SOX17*, *GSC*, *FOXA*2, and *MIXL1* ([Figure S3](#app2){ref-type="sec"}) and no significant upregulation of *SOX7* ([Figure S2](#app2){ref-type="sec"}A).

On confirmation of DE specification, we next sought to specify a hepatic fate. We utilized the same phase II conditions (DMSO) as described above. After the 5 days of treatment, we observed a rapid change in morphology, accompanied with proliferation. For all lines tested, we observed typical hepatic progenitor morphology as assessed by phase contrast microscopy ([Figure S4](#app2){ref-type="sec"}A). We observed efficiencies of between 86% and 89% based on AFP/HNF4A co-expression, as assessed by immunofluorescence ([Figures S4](#app2){ref-type="sec"}B and S4C). Gene expression was analyzed after the end of hepatic specification by qRT-PCR, at which point we observed equivalent expression profiles as hESC H1 ([Figure S4](#app2){ref-type="sec"}D). In addition, as with the hESC line H1, we performed a time course over 5 days and observed a very similar developmental marker profile ([Figure S5](#app2){ref-type="sec"}). The validated hepatic progenitor cells from the different hPSCs were then subjected to phase III differentiation ([Figures 1](#fig1){ref-type="fig"}C and [S1](#app2){ref-type="sec"}C). On completion of the differentiation, all lines efficiently generated smHLCs as assessed by morphology ([Figure S6](#app2){ref-type="sec"}A). All lines demonstrated extensive expression of ALB/ HNF4A and alpha-1-antitrypsin by immunofluorescence ([Figures S6](#app2){ref-type="sec"}B and S6C). Both hESC line 207 and hiPSC-derived smHLCs secreted albumin, alpha-1-antitrypsin, and fibronectin as assessed by ELISA. All three proteins were detected in the medium at levels similar to those observed for H1 ([Figures S7](#app2){ref-type="sec"}A). We demonstrated that the hiPSC-derived smHLCs were from a DE origin via the presence of *CYP7A1* ([Figure S7](#app2){ref-type="sec"}B). We observed comparable efficiency of smHLC production to hESC H1 (between 72% and 79% for ALB/HNF4A and between 88% and 92% for A1AT; [Figure S7](#app2){ref-type="sec"}C). Finally we assessed the expression levels of the following hepatocyte markers: *A1AT (SERPINA1)*, *AFP*, *ALB*, *APOA2*, *ASGR1*, *CYP3A4*, *HNF4A*, *TDO2*, and *TTR* by qRT-PCR, and profiles very similar to H1-derived smHLCs were observed ([Figure S7](#app2){ref-type="sec"}C). Thus, we demonstrated that our protocol was applicable to other hESC and hiPSC lines.

Discussion {#sec3}
==========

We have developed a protocol for the efficient differentiation of functional HLCs from hPSCs that does not require the addition of recombinant growth factors and is applicable to both hESCs and hiPSCs. During the development of the protocol, it came as a surprise to discover that pluripotent cells can be differentiated to DE with a short pulse (24 hr) of CHIR99021, BIO, or Wnt3a without the inclusion of activin A. The rationale to examine GSK-3 inhibition as a route to producing DE has a basis in the observations of Lickert and colleagues ([@bib13]), who demonstrated that Wnt signaling regulates SOX17 expression. A number of other publications also describe the priming activity of GSK-3 inhibitors such as CHIR99021 ([@bib16; @bib22; @bib44; @bib45]). In this study, we clearly demonstrate that GSK-3 inhibition alone is sufficient to produce DE, a finding that in itself represents an opportunity for major saving in hepatocyte-production costs. Importantly, this first stage provided productive DE, which expressed a battery of DE markers including SOX17 and FOXA2, and passed through the equivalent developmental points as growth factor DE ([Figure 2](#fig2){ref-type="fig"}A). The use of DMSO to drive DE toward a hepatic fate is well established in the field ([@bib17; @bib40; @bib42]), and we show here that it is equally successful when employed following CHIR99021 treatment as with activin A and Wnt3a. We observed a rapid change in morphology, coupled with the appearance of the hepatic progenitor markers HNF4A and AFP, both at the transcriptional and protein levels. The final phase of this protocol was to take hepatic progenitors and provide the environment for hepatocyte maturation in order to generate HLCs. We chose to utilize a combination of two small molecules of the glucocorticoid family, DEX and hydrocortisone-21-hemisuccinate (HC), and assessed the literature for potential mimetics of commonly used growth factors. We identified a potent HGF mimetic called N-hexanoic-Tyr, Ile-(6) aminohexanoic amide, or dihexa, originally developed as an anti-dementia drug ([@bib27]). This molecule was identified in a screen that assessed the capacity to potentiate the biological activity of HGF. We therefore employed the small molecules DEX, HC and dihexa in phase III of the protocol. Initially, phase III was optimized using the commercially available base medium HepatoZYME that has been shown to provide supportive conditions for hepatocyte maturation ([@bib43]). We demonstrated the dependency of dihexa in this system (data not shown), but it transpired that HepatoZYME is not growth factor free and contains the morphogen EGF ([@bib14]). We then translated our findings to the routinely used hepatocyte maturation medium L-15, which others have used supplemented with a combination of growth factors and small molecules ([@bib17; @bib42]). We supplemented L-15 with the aforementioned small molecules and efficiently generated HLCs from both hESCs and hiPSCs, which displayed typical hepatic morphology and expressed a number of hepatic markers at the transcriptional and protein levels. More importantly, the smHLCs exhibited key functional attributes including serum protein production and cytochrome P450 metabolism. It should be stated that we used the P450-Glo assay system (Promega) to initially assess function with respect to CYP activity as in line with many other publications. But, in order to gain a thorough insight into the metabolic potential of these cells, we will need to assess them using the more robust and accepted methods including mass spectrometry and high-performance liquid chromatography. It should be noted that the above method is not fully defined at this point, as the present L-15 formulation contains 8.3% serum. We are currently investigating avenues to generate a completely defined system for the production of hepatocytes, but the method described here represents a significant step toward this goal and is applicable to both hESC and hiPSC lines. Importantly, it provides a means to cut the costs associated with hepatocyte production. A combination of this small-molecule approach with the steadily advancing field of cell-culture automation may eventually allow for the production of high-quality hepatocytes from stem cells at large scale for industrial and clinical translation. In the meantime, this approach in our hands produces cells of equivalent phenotype and function to current approaches and addresses some of the cost, quality, and supply-chain concerns associated with reliance on recombinant growth factors.

In conclusion, we demonstrate here the efficient generation of both hESC- and hiPSC-derived HLCs through the use of small molecules, removing the longstanding reliance on recombinant growth factors. This may go on to provide the foundations for scalable hepatocyte production for use in disease modeling, cell therapy, drug discovery, and basic research in terms of improving maturity and function in vitro.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

H1 hESCs (WiCell) and 207 hESCs ([@bib41]) and Detroit 551 (ATCC CCL-110) hiPSCs were maintained at 37°C/5% CO~2~ in feeder-free conditions using growth-factor-reduced Matrigel (Sigma-Aldrich) and E8 Medium (Life Technologies), with routine passaging performed at a 1:3 ratio using 0.5 mM EDTA (Life Technologies). All Matrigel plates were coated with a 1:48 dilution in Advanced DMEM-F12 (Life Technologies) and incubated at 37°C/5% CO~2~ for 1 hr prior to use.

Hepatocyte Differentiation {#sec4.2}
--------------------------

Cells were seeded onto Matrigel-coated 12-well plates in E8 medium at a 1:3--1:4 split ratio and allowed to adhere for 24 hr at 37°C/5% CO~2~. It should be noted that the optimal cell density for each line needs to be established. The cells were washed with PBS before being treated with differentiation media. The differentiation protocol utilizes a base media similar to a well-established differentiation protocol ([@bib17]), with replacement of all growth factors with small molecules and minor adjustments in timing. The protocol incorporates several stages ([Figure 1](#fig1){ref-type="fig"}) utilizing different small molecules.

Phase I of differentiation consists of a 24-hr treatment with RPMI-B27 ± insulin (RPMI 1640 GlutaMAX + B27 supplement, both from Life Technologies) plus 3--4 μM CHIR99021 (Stemgent), followed by a 24-hr treatment with RPMI-B27 alone. Phase II consists of 5 days of treatment with knockout DMEM containing 20% knockout serum replacement, 2 mM GlutaMAX, 100 μM 2-mercaptoethanol, 1× MEM non-essential amino acids (Life Technologies), and 1% DMSO (Sigma-Aldrich). Phase III consists of 10 days of treatment with Leibovitz L-15 media containing 8.3% tryptose phosphate broth, 10 μM hydrocortisone 21-hemisuccinate, 50 μg/ml sodium-L-ascorbate, 100 nM dexamethasone (all from Sigma-Aldrich), 0.58% insulin-transferrin-selenium (ITS), 2 mM GlutaMAX (all from Life Technologies), 8.3% fetal bovine serum (Lonza), and 100 nM dihexa (a kind gift from Prof. Joseph Harding, Washington State University). During phases II and III, cells are fed every 48 hr. Cells were photographed during differentiation using a Zeiss phase contrast microscope and ZEN software. The scale bars represent 100 μm.

Control H1 hESCs (growth factor) were differentiated using activin A, Wnt3a, DMSO, OSM, and HGF (Peprotech) as described previously ([@bib17; @bib42]). All small molecules were made up in DMSO; vehicle control differentiations were performed using equivalent concentrations.

Small Molecules {#sec4.3}
---------------

For a complete list of small molecules, sources, and purity, please see [Table S4](#app2){ref-type="sec"}.

Detailed methods are described in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.
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![Schematic of the Differentiation Process\
(A) The normal process of differentiation and the phases of the protocol to which these apply.\
(B) Summary of the base media, time course, and small-molecule additions for each phase of differentiation.\
(C) Key markers expressed at each stage of differentiation.\
(D) Representative morphology of H1 cells observed at key stages of differentiation using phase contrast microscopy (10×). Scale bars, 100 μm.\
See also [Figure S1](#app2){ref-type="sec"}.](gr1){#fig1}

![Characterization of Phase I Differentiation: Definitive Endoderm\
(A) Gene expression changes during phase I of differentiation as measured by TaqMan qRT-PCR. Blue progression, small-molecule treatment after 24 and 48 hr. Green progression, vehicle control at 24 and 48 hr. Yellow-red progression, published growth-factor-based method ([@bib17]) at 24, 48, and 72 hr. All were performed using H1 hESCs and normalized to *ACTB* and undifferentiated control. Data are presented as the mean of three independent experiments; error bars represent SD.\
(B) Comparison of morphology of growth factor and small-molecule definitive endoderm differentiation at days 0, 1, and 3 for growth factor and days 0, 1, and 2 for small molecule, taken using phase contrast microscopy (10×). Scale bars, 100 μm.\
(C) Expression of FOXA2 and SOX17 at phase I endpoint after treatment with activin/Wnt3a, CHIR99021, BIO, or Wnt3a alone, imaged using fluorescent microscopy. The treatment is indicated at the head of each column. Scale bars, 100 μm.\
(D) Efficiency of phase I differentiation, determined by counting FOXA2-positive cells and SOX17-positive cells. Efficiencies are presented as the percentage of positive cells plus or minus the SD of all fields counted.\
See also [Figure S2](#app2){ref-type="sec"}.](gr2){#fig2}

![Phase I 48-Hr Time Course to Assess Developmental Trajectory by qRT-PCR\
The human embryonic stem cell line H1 was differentiated in RPMI-B27 supplemented with 3 μM CHIR99021. The expression profiles of key genes were examined to establish the dynamics of the differentiation process. We monitored developmentally relevant markers of primitive streak (*T*, *MIXL1*, *GSC*, and *FOXA2*), mesendoderm (*T* and *FOXA2*), and definitive endoderm (*HHEX*, *CER1*, *SOX17*, and *FOXA2*). Cells were collected for analysis every 4 hr for 48 hr (phase I: DE stage). Data are presented as the mean of three independent experiments; error bars represent SD. The x axis represents the time (in hours) after the start of differentiation. The y axis represents the log10 relative quantification (RQ) values from the TaqMan analysis. See also [Figure S3](#app2){ref-type="sec"}.](gr3){#fig3}

![Characterization of Phase II Differentiation: Hepatic Specification\
(A) Expression of AFP and HNF4A at phase II endpoint of growth-factor- and small-molecule-treated cells, imaged using fluorescent microscopy. Treatment is indicated at the head of each column. Scale bars, 100 μm.\
(B) Efficiency of phase II differentiation, determined by counting AFP and HNF4A double-positive cells. Efficiencies are presented as the percentage of positive cells plus or minus the SD of all fields counted.\
(C) Morphology at phase II endpoint, photographed using phase contrast microscopy at 10× and 20×. Scale bars, 100 μm.\
(D) Expression of *AFP CEBPA*, *FOXA2*, *GATA4*, *HHEX*, *HNF4A*, *PROX1*, *SOX17*, *TBX3*, and *TTR* at phase II endpoint following either growth-factor (red) or small-molecule (blue) treatments, as measured by TaqMan. Normalized to *ACTB* and growth-factor- or small-molecule-derived definitive endoderm, respectively. Data are presented as the mean of three independent experiments; error bars represent SD.\
See also [Figure S4](#app2){ref-type="sec"}.](gr4){#fig4}

![Phase II 5-Day Time Course\
The human embryonic stem cell line H1 was differentiated to definitive endoderm using either the small-molecule (blue) or growth-factor (red) protocol. Definitive endoderm was treated with 1% DMSO to differentiate to hepatic progenitors, and cells were collected every 24 hr for 5 days to assess the gene expression of developmentally relevant hepatic markers. Data are presented as the mean of three independent experiments; error bars represent SD. The x axis represents the time (in days) after definitive endoderm. The y axis represents the RQ values from the TaqMan analysis. See also [Figure S5](#app2){ref-type="sec"}.](gr5){#fig5}

![Characterization of Phase III Differentiation to Hepatocyte-like Cells: Morphology and Immunofluorescence\
(A) Morphology of growth-factor and small-molecule protocol endpoints, taken using phase contrast microscopy at 10×. Scale bars, 100 μm.\
(B) Expression of albumin and HNF4A at protocol endpoints, imaged using fluorescent microscopy. Treatment is indicated at the head of each column. Scale bars, 100 μm.\
(C) Expression of A1AT at protocol endpoints, imaged using fluorescent microscopy. Treatment is indicated at the head of each column. Scale bars, 100 μm.\
(D) Expression of AFP at protocol endpoint was imaged using fluorescent microscopy. Treatment is indicated at the head of each column. Scale bars, 100 μm.\
(E) Efficiency of phase III differentiation, determined by counting albumin and HNF4A double-positive cells, A1AT-positive cells, and AFP-positive cells. Efficiencies are presented as the percentage of positive cells plus or minus the SD of all fields counted.\
(F) RT-PCR of *CYP7A1* gene expression of H1-derived smHLCs. Lane 1, hESC H1 control; lanes 2--4 (top panel), H1 day 17 HLCs *CYP7A1* expression; lanes 2--4 (lower panel), *ACTB* loading control.\
See also [Figure S6](#app2){ref-type="sec"}.](gr6){#fig6}

![Characterization of Phase III Differentiation to Hepatocyte-like Cells: qRT-PCR and Functional Analysis\
(A) Expression of *A1AT (SERPINA1)*, *AFP*, *ALB*, *APOA2*, *ASGR1*, *CYP3A4*, *HNF4A*, *TDO2*, and *TTR* at endpoint of small-molecule (blue) and growth-factor (red) protocols, as well as primary adult and fetal hepatocyte controls, assessed by TaqMan. Normalized to *ACTB* and small-molecule- or growth-factor-derived definitive endoderm, respectively. Data are presented as the mean of three independent experiments; error bars represent SD. Because only one primary fetal control was run, no error bars are present.\
(B) Cytochrome P450 1A2 and 3A4 activity and induction were assessed in both smHLCs (SM) and growth-factor-derived HLCs (GF). The black columns represent hESC H1 pluripotent control, the blue columns represent basal activity, and the orange columns represent activity after induction with either omeprazole (1A2) or rifampicin (3A4). Data are presented as the mean of six independent experiments; error bars represent SD (n = 6 biological replicates). GF CYP1A2 ^∗^p \< 0.05, ^∗∗^p \< 0.002; SM CYP1A2 ^∗^p \< 0.02, ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. GF CYP3A4 ^∗^p \< 0.001, ^∗∗^p \< 0.005; SM CYP3A4 ^∗^p \< 0.004, ^∗∗^p \< 0.0002; ^∗∗∗^p \< 2 × 10^−5^.\
(C) Serum protein secretion at endpoint of both growth-factor- (red) and small-molecule-based (blue) protocols. Data are presented as the mean of three independent experiments; error bars represent SD. ^∗^p \< 0.09, ^∗∗^p \< 0.004, compared to control.\
(D) Glycogen storage in growth-factor- and small-molecule-differentiated cells as indicated by PAS staining. Treatment is indicated top left of each panel. Scale bars, 100 μm.\
(E) H1 smHLCs treated for 1 hr with 1 mg/ml indocyanine green demonstrate uptake as assessed by phase microscopy. Scale bars, 100 μm.\
See also [Figure S7](#app2){ref-type="sec"}.](gr7){#fig7}
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